Biologic Therapy in HIV: To Screen or Not to Screen

Biologic therapy has revolutionized the management of chronic inflammatory diseases, including inflammatory bowel disease (IBD). Before the initiation of therapy, it is critical to rule out prior infection of chronic hepatitis B virus (HBV) and tuberculosis (TB). However, screening for human immunod...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis, Willam, Vavilin, Ilan, Malhotra, Nidhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Gastroenterology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312554/
https://www.ncbi.nlm.nih.gov/pubmed/34336440
http://dx.doi.org/10.7759/cureus.15941
Descripción
Sumario:Biologic therapy has revolutionized the management of chronic inflammatory diseases, including inflammatory bowel disease (IBD). Before the initiation of therapy, it is critical to rule out prior infection of chronic hepatitis B virus (HBV) and tuberculosis (TB). However, screening for human immunodeficiency virus (HIV) is not as routinely completed. We present a case of a 56-year-old male on ustekinumab for the management of Crohn’s disease, found to have undiagnosed human immunodeficiency virus (HIV) with progression to acquired immunodeficiency syndrome (AIDS). 

Ejemplares similares